Docetaxel
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DOCETAXEL |
|---|---|
| Type | Drug |
| Aliases | DocefrezDocetereTaxotereДоцетаксель |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-BREAST DIS-CRC DIS-ESOPHAGEAL DIS-GASTRIC DIS-NSCLC DIS-PROSTATE DIS-SOFT-TISSUE-SARCOMA |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | Taxane (microtubule stabilizer) |
|---|---|
| Mechanism | Semi-synthetic taxane derived from European yew (Taxus baccata). Binds the β-subunit of polymerized tubulin at the taxane-binding site (~1.9× higher affinity than paclitaxel), promoting microtubule assembly and stabilizing existing microtubules against depolymerization. Cells arrest at G2/M, triggering apoptosis. Solubilized in polysorbate 80 (Tween 80) + ethanol — premedication with corticosteroids critical to prevent fluid retention and hypersensitivity (Cremophor-EL not used in docetaxel). Higher myelosuppression and febrile neutropenia rates than paclitaxel. |
| Typical dosing | Prostate (mHSPC + mCRPC): 75 mg/m² IV q3 weeks × 6 cycles (mHSPC, CHAARTED) or × 10 cycles (mCRPC, TAX-327, until intolerance). Breast adjuvant TAC: 75 mg/m² IV day 1 q21d × 6 (with doxorubicin 50 mg/m² + cyclophosphamide 500 mg/m²). Breast metastatic mono: 60-100 mg/m² IV q21d. NSCLC 2L mono: 75 mg/m² IV q21d. NSCLC 1L (with cisplatin): 75 mg/m² IV q21d. Gastric DCF: 75 mg/m² IV day 1 q21d (with cisplatin + 5-FU). Head and neck TPF induction: 75 mg/m² IV day 1 q21d × 3 (with cisplatin + 5-FU). Mandatory premedication: dexamethasone 8 mg PO BID × 3 days starting day before infusion (to prevent fluid retention and hypersensitivity). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Hepatic dysfunction — increased risk of severe / fatal toxicity (avoid if bilirubin > ULN)
- Severe neutropenia — neutropenic deaths reported
- Severe hypersensitivity reactions
- Severe fluid retention (premedication mandatory; can be fatal)
Notes
Cytotoxic backbone added to ADT for high-volume mHSPC (CHAARTED, STAMPEDE) and as ARASENS triplet partner with darolutamide. mCRPC option (TAX-327) but ARPIs typically preferred 1L if no high-volume burden. Hepatic adjustment essential — bilirubin > ULN requires dose reduction or avoidance. Premedication: dexamethasone 8 mg PO BID × 3 days starting day before to prevent fluid retention + hypersensitivity. G-CSF primary prophylaxis for high febrile- neutropenia risk regimens (TAC, TPF, DCF). Cumulative neuropathy + nail toxicity may be dose-limiting after several cycles.
Used By
Regimens
REG-ADT-DAROLUTAMIDE-DOCETAXEL- ADT + darolutamide + docetaxel (ARASENS triplet)REG-DOCETAXEL-MCRPC- Docetaxel (mCRPC)REG-DOCETAXEL-RAMUCIRUMAB- Docetaxel + Ramucirumab (REVEL) — 2L+ NSCLC post-platinum / post-ICIREG-FLOT- FLOTREG-GEMCITABINE-DOCETAXEL-STS- Gemcitabine + docetaxel (soft tissue sarcoma)REG-TCHP-NEOADJUVANT- TCHP — docetaxel + carboplatin + trastuzumab + pertuzumab (HER2+ neoadjuvant)REG-THP-METASTATIC- THP — docetaxel + trastuzumab + pertuzumab (HER2+ metastatic 1L)